NASDAQ:YARW Yarrow Bioscience Q2 2026 Earnings Results & Report $18.79 -0.84 (-4.28%) As of 11:16 AM Eastern This is a fair market value price provided by Massive. Learn more. Yarrow Bioscience missed analyst expectations on both earnings and revenue in its Q2 2026 results, released August 13, 2026. The company reported EPS of -$3.51 versus the -$0.18 consensus estimate, while revenue of $97 thousand fell short of the $200 thousand estimate by $103.00 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 13, 2026TimeBefore Market OpensConference Call7:00 AM ET Yarrow Bioscience EPS ResultsActual EPS-$3.51Consensus EPS -$0.18Beat/MissMissed by -$3.33One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersYarrow Bioscience Revenue ResultsActual Revenue$97 thousandExpected Revenue$200 thousandBeat/MissMissed by -$103.00 thousandYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Yarrow Bioscience Q2 2026 Earnings FAQ Did Yarrow Bioscience beat earnings estimates for Q2 2026? Yarrow Bioscience (NASDAQ:YARW) reported earnings of -$3.51 per share for Q2 2026, missing the consensus estimate of -$0.18. The report was announced on Thursday, August 13, 2026. What was Yarrow Bioscience's revenue for Q2 2026? Yarrow Bioscience reported revenue of $97 thousand for Q2 2026, against a consensus estimate of $200 thousand. Yarrow Bioscience Earnings HeadlinesYarrow Bioscience Reports Third Quarter 2026 Financial Results and Provides Business UpdateNovember 12 at 7:36 AM | marketscreener.comMYarrow Reports $9.7 Million Third-Quarter Net Loss and $268.9 Million CashNovember 12 at 7:11 AM | quiverquant.comQToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.November 13 at 1:00 AM | Behind the Markets (Ad)Yarrow Bioscience (NASDAQ:YARW) Stock Rated "Buy" in New Coverage at GuggenheimNovember 9, 2026 | americanbankingnews.comGuggenheim starts Yarrow Bioscience at Buy, citing Graves’ disease potentialNovember 6, 2026 | finance.yahoo.comGuggenheim Initiates Coverage on Yarrow Bioscience With Buy Rating, $60 Price TargetNovember 6, 2026 | marketscreener.comMSee More Yarrow Bioscience Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Yarrow Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Yarrow Bioscience and other key companies, straight to your email. Email Address About Yarrow BioscienceVYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.View Yarrow Bioscience ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Costco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsThese 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffSix Flags Lost $366 Million in Q3—Its Insiders Just Went ShoppingGolden Dome’s $185 Billion Question: Who Actually Gets Paid?3 Pharmaceutical Stocks That Offer Safety and GrowthKeeping AI Cool: AAON Rides the AI Heatwave to Record Growth Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
